Kennedy Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.72M | Sell |
53,478
-4,176
| -7% | -$525K | 0.16% | 223 |
|
|
2025
Q1 | $6.38M | Buy |
57,654
+21,542
| +60% | +$2.38M | 0.15% | 231 |
|
|
2024
Q4 | $4.93M | Buy |
36,112
+5,093
| +16% | +$695K | 0.11% | 332 |
|
|
2024
Q3 | $3.57M | Buy |
31,019
+2,539
| +9% | +$293K | 0.08% | 388 |
|
|
2024
Q2 | $3.92M | Sell |
28,480
-4,756
| -14% | -$655K | 0.08% | 374 |
|
|
2024
Q1 | $4.58M | Buy |
33,236
+11,850
| +55% | +$1.63M | 0.09% | 343 |
|
|
2023
Q4 | $2.82M | Sell |
21,386
-30,185
| -59% | -$3.98M | 0.06% | 424 |
|
|
2023
Q3 | $5.8M | Sell |
51,571
-5,094
| -9% | -$573K | 0.14% | 257 |
|
|
2023
Q2 | $5.34M | Buy |
56,665
+10,032
| +22% | +$946K | 0.12% | 278 |
|
|
2023
Q1 | $4.72M | Buy |
46,633
+23,673
| +103% | +$2.4M | 0.14% | 271 |
|
|
2022
Q4 | $2.74M | Sell |
22,960
-925
| -4% | -$110K | 0.08% | 377 |
|
|
2022
Q3 | $2.54M | Buy |
23,885
+19,899
| +499% | +$2.11M | 0.07% | 384 |
|
|
2022
Q2 | $389K | Buy |
+3,986
| New | +$389K | 0.01% | 561 |
|